📰 Nuclear Export News
Page 14 - Nuclear Export News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nuclear Export. Real-time updates on events, politics, business and more.
June 1, 2022
Wall Street brokerages predict that Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) will post earnings of ($0.63) per share for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Karyopharm Therapeutics’ earnings, with estimates ranging from ($0.81) to ($0.50). Karyopharm Therapeutics reported earnings of ($0.71) per share during the same quarter […]
June 1, 2022
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...
May 26, 2022
– Encouraging Initial Data Observed in Phase 1/2 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis, Including Favorable...
May 25, 2022
/PRNewswire/ -- The European Myeloma Network (EMN), an international collaborative network of expertise centers for multiple myeloma in Europe and Australia,...
May 20, 2022
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group...
May 20, 2022
-- European Commission Decision Anticipated within Approximately 60 Days -- NEWTON, Mass. and FLORENCE, Italy, May 20, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI),
May 12, 2022
/PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...
May 5, 2022
– Achieved First Quarter 2022 Net Revenues of $47.7 Million, Up 105% Versus First Quarter 2021, Including $19.4 Million License Revenues from Partners – –...
May 2, 2022
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...
April 28, 2022
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it...